io9, Inc.

Our CEO, Greg Hamilton, and CSO, Ludmil B. Alexandrov recently sat down with Precision Medicine Online and GenomeWeb to discuss the recent findings of our #AI-powered biomarker test published in American Society of Clinical Oncology (ASCO)'s Journal of Clinical Oncology. Developed on the OncoGaze platform, DeepHRD aims to transform cancer treatment offering a quicker and more cost-effective alternative to traditional next-generation sequencing (NGS) tests.   Greg also provided insight into the next steps in advancing the technology, prioritizing partnerships, with the goal to make #precisionmedicine more accessible and efficient, especially in regions where NGS testing is not readily available.   Read more here: https://lnkd.in/g-r8Nm5U

io9 is on a mission is to revolutionize #precisiononcology by enabling the correct front-line precision therapy selection at diagnosis. Our CEO Greg Hamilton and CSO Ludmil B. Alexandrov sat down with Jonathan D. Grinstein, PhD at Inside Precision Medicine to discuss our recently published data highlighting OncoGaze™’s superior ability to identify HRD-positive #cancer patients, expand the treatable patient population and integrate #pathologists into first-line precision oncology workflows. Read the article here: https://lnkd.in/ewwwaTdT. #AI

Our CEO, Greg Hamilton, connected with BiotechTV’s Brian Orelli, PhD following the positive study published yesterday in the Journal of Clinical Oncology about our #AI-powered biomarker test, DeepHRD. Watch the video below to learn how we are working to revolutionize #cancer treatment decisions by ensuring that more patients receive the correct first-line treatments promptly, reducing delays, cost and increasing access to #precisiononcology medicines. Watch the full video here: https://lnkd.in/g-6Rp3bT

A positive validation study for OncoGaze™, our #AI-biomarker platform designed to identify clinically actionable biomarkers, has been published in American Society of Clinical Oncology (ASCO)'s  Journal of Clinical Oncology. This groundbreaking research demonstrates the efficacy of DeepHRD, our first #cancer #biomarker test, in identifying patients with Homologous Recombination Deficiency (HRD) from routine tissue slides. The study highlighted that DeepHRD outperformed FDA-approved HRD companion diagnostics by increasing the treatable patient population 1.8 to 3.1-fold. Our collaboration with UC San Diego has been instrumental in achieving this milestone. Together, we're working to eliminate delays and inequities in #cancer treatment selection and to provide better outcomes for ovarian and breast cancer patients. Read the full press release to learn more about how #OncoGaze aims to transform #precisiononcology landscape: https://lnkd.in/gKCjW97P #HealthcareInnovation #UCSD #JCO #io9 #metastaticbreastcancer #BCSM #ovariancancer.